7f7e: Difference between revisions
New page: '''Unreleased structure''' The entry 7f7e is ON HOLD Authors: Dou, Y., Wang, X., Wang, K., Liu, P., Lu, B. Description: SARS-CoV-2 S protein RBD in complex with A5-10 Fab [[Category: U... |
No edit summary |
||
| (4 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
The | ==SARS-CoV-2 S protein RBD in complex with A5-10 Fab== | ||
<StructureSection load='7f7e' size='340' side='right'caption='[[7f7e]], [[Resolution|resolution]] 2.49Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[7f7e]] is a 3 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] and [https://en.wikipedia.org/wiki/Severe_acute_respiratory_syndrome_coronavirus_2 Severe acute respiratory syndrome coronavirus 2]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7F7E OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7F7E FirstGlance]. <br> | |||
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.49Å</td></tr> | |||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7f7e FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7f7e OCA], [https://pdbe.org/7f7e PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7f7e RCSB], [https://www.ebi.ac.uk/pdbsum/7f7e PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7f7e ProSAT]</span></td></tr> | |||
</table> | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
The neutralizing antibody is a potential therapeutic for the ongoing COVID-19 pandemic. As an antiviral agent, numerous mAbs recognize the epitopes that overlap with ACE2-binding sites in the SARS-CoV-2-RBD. Some studies have shown that residual changes on the spike protein can significantly decrease the efficiency of neutralizing antibodies. To address this issue, a therapeutic cocktail could be an effective countermeasure. In the present study, we isolated a fully human neutralizing antibody, JS026, from a convalescent patient. The comparative analysis revealed that JS026 binding to SARS-CoV-2-RBD mainly located between epitopes for class 2 and class 3 mAbs as opposed to that of class 1 (etesevimab) antibodies. A cocktail of etesevimab and JS026 increased neutralizing efficacy against both wild-type SARS-CoV-2 and the recent emergence of Alpha, Beta, Gamma, and Delta variants. JS026 and the cocktail reduced virus titers in the infected lungs of hACE2 transgenic mice and relieved pathological changes. These findings would benefit antibody-based therapeutic countermeasures in the treatment of COVID-19. | |||
Etesevimab in combination with JS026 neutralizing SARS-CoV-2 and its variants.,Wang F, Li L, Dou Y, Shi R, Duan X, Liu H, Zhang J, Liu D, Wu J, He Y, Lan J, Lu B, Feng H, Yan J Emerg Microbes Infect. 2022 Dec;11(1):548-551. doi: , 10.1080/22221751.2022.2032374. PMID:35060840<ref>PMID:35060840</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
[[Category: | </div> | ||
[[Category: | <div class="pdbe-citations 7f7e" style="background-color:#fffaf0;"></div> | ||
[[Category: Liu | |||
[[Category: | ==See Also== | ||
[[Category: Wang | *[[Antibody 3D structures|Antibody 3D structures]] | ||
[[Category: Wang | *[[Spike protein 3D structures|Spike protein 3D structures]] | ||
== References == | |||
<references/> | |||
__TOC__ | |||
</StructureSection> | |||
[[Category: Homo sapiens]] | |||
[[Category: Large Structures]] | |||
[[Category: Severe acute respiratory syndrome coronavirus 2]] | |||
[[Category: Dou Y]] | |||
[[Category: Liu P]] | |||
[[Category: Lu B]] | |||
[[Category: Wang K]] | |||
[[Category: Wang X]] | |||